A phase 1 dosing study of ruxolitinib in children with relapsed or refractory solid tumors, leukemias, or myeloproliferative neoplasms: A Children's Oncology Group phase 1 consortium study (ADVL1011)

Ruxolitinib, an orally bioavailable JAK1/JAK2 inhibitor, may treat cancers with CRLF2 and/or JAK pathway mutations.

[1]  Heather L. Mulder,et al.  Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. , 2014, The New England journal of medicine.

[2]  N. Heerema,et al.  Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children's Oncology Group Study AALL0031 , 2014, Leukemia.

[3]  O. Abdel-Wahab,et al.  Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon α-2a. , 2013, Blood.

[4]  H. Kantarjian,et al.  Acute lymphoblastic leukemia in adults: encouraging developments on the way to higher cure rates , 2013, Leukemia & lymphoma.

[5]  A. Quintás-Cardama,et al.  Molecular Pathways: JAK/STAT Pathway: Mutations, Inhibitors, and Resistance , 2013, Clinical Cancer Research.

[6]  M. Loh,et al.  Tyrosine kinome sequencing of pediatric acute lymphoblastic leukemia: a report from the Children's Oncology Group TARGET Project. , 2013, Blood.

[7]  J. Shah,et al.  Phase I study of a novel oral Janus kinase 2 inhibitor, SB1518, in patients with relapsed lymphoma: evidence of clinical and biologic activity in multiple lymphoma subtypes. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  M. Loh,et al.  Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia. , 2012, Blood.

[9]  Ryan D. Morin,et al.  Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia. , 2012, Cancer cell.

[10]  Julie M Gastier-Foster,et al.  Aberrant STAT5 and PI3K/mTOR pathway signaling occurs in human CRLF2-rearranged B-precursor acute lymphoblastic leukemia. , 2012, Blood.

[11]  M. Carroll,et al.  Single-Cell Pharmacodynamic Monitoring of S6 Ribosomal Protein Phosphorylation in AML Blasts during a Clinical Trial Combining the mTOR Inhibitor Sirolimus and Intensive Chemotherapy , 2011, Clinical Cancer Research.

[12]  P. Scherle,et al.  The Pharmacokinetics, Pharmacodynamics, and Safety of Orally Dosed INCB018424 Phosphate in Healthy Volunteers , 2011, Journal of clinical pharmacology.

[13]  Michael N. Edmonson,et al.  Key pathways are frequently mutated in high-risk childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group. , 2011, Blood.

[14]  C. Pui.  Recent Advances in Acute Lymphoblastic Leukemia , 2011 .

[15]  Ayalew Tefferi,et al.  Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. , 2010, The New England journal of medicine.

[16]  J. Downing,et al.  Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia. , 2010, Blood.

[17]  P. D. Dal Cin,et al.  Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia , 2009, Proceedings of the National Academy of Sciences.

[18]  N. Heerema,et al.  Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  J. Downing,et al.  Rearrangement of CRLF2 in B-progenitor– and Down syndrome–associated acute lymphoblastic leukemia , 2009, Nature Genetics.

[20]  Takashi Akasaka,et al.  Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia. , 2009, Blood.

[21]  M. Loh,et al.  JAK mutations in high-risk childhood acute lymphoblastic leukemia , 2009, Proceedings of the National Academy of Sciences.

[22]  M. Griesshammer,et al.  Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference. , 2009, Blood.

[23]  G. Wainreb,et al.  Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome , 2008, The Lancet.

[24]  Jeffrey S Barrett,et al.  Shortening the timeline of pediatric phase I trials: the rolling six design. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  E. Estey,et al.  Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors. , 2006, Blood.

[26]  W. Abdullah.  Pediatr Blood Cancer , 2004 .

[27]  A. Verma,et al.  Jak family of kinases in cancer , 2003, Cancer and Metastasis Reviews.

[28]  J. Rowe,et al.  Stem cell transplantation in adult ALL patients. , 2002, Best practice & research. Clinical haematology.

[29]  C. Schindler,et al.  Series Introduction: JAK-STAT signaling in human disease , 2002 .

[30]  M. Loh,et al.  Targeting JAK 1 / 2 and mTOR in Murine Xenograft Models of Ph-like Acute Lymphoblastic Leukemia ( ALL ) , 2012 .

[31]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.